Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Galectin Therapeutics Inc (GALT)
NASDAQ:GALT
RESEARCH TOOLSreports
Holding GALT?
Track your performance easily
GALT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.56 - $4.27
Previous Close$2.82
Volume141.29K
Average Volume (3M)137.75K
Market Cap
$172.91M
Enterprise Value$218.79M
Total Cash (Recent Filing)$27.06M
Total Debt (Recent Filing)$72.94M
Price to Earnings (P/E)―
Beta1.15
Next Earnings
Mar 27, 2025EPS Estimate
-$0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.73
Shares Outstanding62,761,825
10 Day Avg. Volume167,634
30 Day Avg. Volume137,750
Standard Deviation0.24
R-Squared0.02
Alpha0.00701
Financial Highlights & Ratios
Price to Book (P/B)-1.86
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-5.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-5.07
Forecast
1Y Price Target
$11.00Price Target Upside304.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Galectin Therapeutics News
PremiumCompany Announcements
Galectin Therapeutics Reports Increased Q3 Losses
PremiumCompany Announcements
Galectin Therapeutics Advances Galectin-Based Therapeutics Pipeline
PremiumCompany Announcements
Galectin Therapeutics Unveils Future Plans and Drug Potential
Ownership Overview
27.87% Insiders
4.59% Mutual Funds
5.68% Other Institutional Investors
57.40% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
GALT FAQ
What was Galectin Therapeutics Inc’s price range in the past 12 months?
Galectin Therapeutics Inc lowest stock price was $1.55 and its highest was $4.27 in the past 12 months.
What is Galectin Therapeutics Inc’s market cap?
Currently, no data Available
When is Galectin Therapeutics Inc’s upcoming earnings report date?
Galectin Therapeutics Inc’s upcoming earnings report date is Mar 27, 2025 which is in 126 days.
How were Galectin Therapeutics Inc’s earnings last quarter?
Galectin Therapeutics Inc released its earnings results on Nov 14, 2024. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.2 by $0.02.
Is Galectin Therapeutics Inc overvalued?
According to Wall Street analysts Galectin Therapeutics Inc’s price is currently Undervalued.
Does Galectin Therapeutics Inc pay dividends?
Galectin Therapeutics Inc does not currently pay dividends.
What is Galectin Therapeutics Inc’s EPS estimate?
Galectin Therapeutics Inc’s EPS estimate is -$0.16.
How many shares outstanding does Galectin Therapeutics Inc have?
Galectin Therapeutics Inc has 62,761,826 shares outstanding.
What happened to Galectin Therapeutics Inc’s price movement after its last earnings report?
Galectin Therapeutics Inc reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.2. Following the earnings report the stock price went down -5.172%.
Which hedge fund is a major shareholder of Galectin Therapeutics Inc?
Currently, no hedge funds are holding shares in GALT
---
Galectin Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.00 (304.41% Upside)
$11.00 (304.41% Upside)
Insider Transactions
Bought Shares
Worth $39.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
50.53%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
30.72%
Trailing 12-Months
Company Description
Galectin Therapeutics Inc
Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs targets the development of carbohdrate molecules which offers offer alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.
---
GALT Stock 12 Month Forecast
Average Price Target
$11.00
▲(304.41% Upside)
Technical Analysis
Best Analysts Covering GALT
1 Year
1 Year Success Rate
11/17 ratings generated profit
1 Year Average Return
+12.45%
reiterated a buy rating 7 days ago
Copying Ed Arce's trades and holding each position for 1 Year would result in 64.71% of your transactions generating a profit, with an average return of +12.45% per trade.
---